Safety and immunogenicity of homologous prime-boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study.

Safety and immunogenicity of homologous prime-boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study.

Publication date: Jan 01, 2024

People living with HIV (PLWH) are particularly vulnerable to SARS-CoV-2. This multicentre prospective cohort study evaluated the long-term immunogenicity and safety of a third homologous dose of Sinovac CoronaVac in PLWH in China. A total of 228 PLWH and 127 HIV-negative controls were finally included and followed up for 6 months. Fewer participants reported mild or moderate adverse reactions, and no serious adverse events were observed. The median levels of neutralizing antibodies (nAbs) and immunoglobulin G against the receptor-binding domain of the spike protein (S-IgG) in PLWH (655. 92 IU/mL, IQR: 175. 76-1663. 55; 206. 83 IU/mL, IQR: 85. 20-397. 82) were comparable to those in control group (1067. 16 IU/mL, IQR: 239. 85-1670. 83; 261. 70 IU/mL, IQR: 77. 13-400. 75), and reached their peak at 4 weeks, exhibiting a delayed peak pattern compared to the 2-week peak in control group. After then, the immune titres gradually decreased over time, but most participants still maintained positive seroconversion at the 6-month mark. Multivariable generalized estimating equation analysis indicated that CD4+T cell count, HIV viral load, and antiretroviral therapy (ART) were independent factors strongly associated with immune response (each p 

Concepts Keywords
China adverse events
Hiv Antibodies, Neutralizing
Month Antibodies, Neutralizing
Therapy Antibodies, Viral
Antibodies, Viral
CD4 Lymphocyte Count
China
COVID-19 Vaccines
COVID-19 Vaccines
Humans
Immunogenicity, Vaccine
neutralizing antibody
PLWH
Prospective Studies
S-IgG antibody
Sinovac CoronaVac
sinovac COVID-19 vaccine
Vaccines, Inactivated
Vaccines, Inactivated

Semantics

Type Source Name
disease VO CoronaVac
disease VO vaccine
disease VO dose
disease VO time
disease MESH seroconversion
disease IDO cell
disease IDO immune response
disease MESH COVID-19
disease VO COVID-19 vaccine

Original Article

(Visited 1 times, 1 visits today)